Over the past decade, monoclonal antibodies targeting programmed cell death protein 1 (PD-1) or its ligand PD-L1 have been globally approved for clinical use, either as monotherapy or in combination with chemotherapy, for the treatment of various malignancies, including thoracic cancers such as mesothelioma (Table 1). Here, PDCD1 is linked to mesothelioma.